JP2023536264A5 - - Google Patents
Info
- Publication number
- JP2023536264A5 JP2023536264A5 JP2023506226A JP2023506226A JP2023536264A5 JP 2023536264 A5 JP2023536264 A5 JP 2023536264A5 JP 2023506226 A JP2023506226 A JP 2023506226A JP 2023506226 A JP2023506226 A JP 2023506226A JP 2023536264 A5 JP2023536264 A5 JP 2023536264A5
- Authority
- JP
- Japan
- Prior art keywords
- cancer
- approximately
- combination according
- compound
- administered
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063059601P | 2020-07-31 | 2020-07-31 | |
| US63/059,601 | 2020-07-31 | ||
| US202063113556P | 2020-11-13 | 2020-11-13 | |
| US63/113,556 | 2020-11-13 | ||
| US202163148921P | 2021-02-12 | 2021-02-12 | |
| US63/148,921 | 2021-02-12 | ||
| PCT/US2021/043699 WO2022026706A1 (en) | 2020-07-31 | 2021-07-29 | Combinations for the treatment of cancer |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2023536264A JP2023536264A (ja) | 2023-08-24 |
| JP2023536264A5 true JP2023536264A5 (enExample) | 2024-08-05 |
| JP7847576B2 JP7847576B2 (ja) | 2026-04-17 |
Family
ID=77431400
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023506226A Active JP7847576B2 (ja) | 2020-07-31 | 2021-07-29 | がんの治療のための組み合わせ |
Country Status (18)
| Country | Link |
|---|---|
| US (1) | US20230301979A1 (enExample) |
| EP (1) | EP4188376A1 (enExample) |
| JP (1) | JP7847576B2 (enExample) |
| KR (1) | KR20230059792A (enExample) |
| CN (1) | CN116437954A (enExample) |
| AU (1) | AU2021318134A1 (enExample) |
| BR (1) | BR112023001792A2 (enExample) |
| CA (1) | CA3186517A1 (enExample) |
| CL (1) | CL2023000289A1 (enExample) |
| CO (1) | CO2023001561A2 (enExample) |
| CR (1) | CR20230052A (enExample) |
| GE (1) | GEAP202616896A (enExample) |
| IL (1) | IL300151A (enExample) |
| MX (1) | MX2023001298A (enExample) |
| PE (1) | PE20231369A1 (enExample) |
| PH (1) | PH12023550160A1 (enExample) |
| TW (1) | TW202220654A (enExample) |
| WO (1) | WO2022026706A1 (enExample) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GEAP202415420A (en) * | 2018-01-26 | 2024-12-25 | Exelixis Inc | Compounds for the treatment of kinase-dependent disorders |
| KR20220163940A (ko) | 2020-02-04 | 2022-12-12 | 시애틀 칠드런즈 호스피탈 디/비/에이 시애틀 칠드런즈 리서치 인스티튜트 | 항-디니트로페놀 키메라 항원 수용체 |
| US20230326575A1 (en) * | 2020-04-29 | 2023-10-12 | Societe Des Produits Nestle S.A. | System and method for providing fertility enhancing dietary recommendations in individuals with low testosterone |
| WO2021219579A1 (en) * | 2020-04-29 | 2021-11-04 | Société des Produits Nestlé S.A. | System and method for providing fertility enhancing dietary recommendations in individuals with sperm conditions |
| JP2025509343A (ja) * | 2022-03-07 | 2025-04-11 | サノフィ－アベンティス・ユー・エス・エルエルシー | 多発性骨髄腫の治療のための他の薬剤と組み合わせたイサツキシマブの使用 |
| EP4504264A4 (en) * | 2022-04-08 | 2026-03-11 | Global Cancer Tech Inc | METHODS AND PRODUCTS FOR SCREENING AND TREATMENT OF GLIOBLASTOMA MULTIFORME AND OTHER CANCERS, INCLUDING BREAST CANCERS, USING A COMBINATION OF PI3KINASE INHIBITORS WITH CHECKPOINT INHIBITORS |
| CN120390641A (zh) * | 2022-10-19 | 2025-07-29 | 西雅图儿童医院（Dba西雅图儿童研究所） | 采用靶向小分子和抗靶向car t细胞的治疗方法 |
| EP4665766A2 (en) * | 2023-02-13 | 2025-12-24 | LAVA Therapeutics N.V. | Combination therapy comprising multispecific gamma delta tcr antibodies |
| EP4450972A1 (en) * | 2023-04-21 | 2024-10-23 | Fundación Instituto de Investigación Sanitaria de Santiago de Compostela | In vitro method for predicting cancer patient response to pd-1 and/or pd-l1 inhibitors |
| CN117285533B (zh) * | 2023-11-24 | 2024-01-30 | 四川省医学科学院·四川省人民医院 | CD47/SIRPα小分子抑制剂及其应用和抗肿瘤药物组合物 |
| KR20260016691A (ko) * | 2024-07-25 | 2026-02-04 | 서울대학교산학협력단 | Tpst2 억제제 또는 ifngr1의 황산화 억제제를 포함하는 암의 예방 또는 치료용 조성물 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR112015007672A2 (pt) | 2012-10-04 | 2017-08-08 | Dana Farber Cancer Inst Inc | anticorpos anti-pd-l1 monoclonais humanos e métodos de uso |
| JP6742903B2 (ja) | 2013-05-02 | 2020-08-19 | アナプティスバイオ インコーポレイティッド | プログラム死−１（ｐｄ−１）に対する抗体 |
| JP2019529476A (ja) * | 2016-09-27 | 2019-10-17 | ザ ユナイテッド ステイツ オブ アメリカ， アズ リプレゼンテッド バイ ザ セクレタリー， デパートメント オブ ヘルス アンド ヒューマン サービシーズ | Ｎ−（４−（６，７−ジメトキシキノリン−４−イルオキシ）フェニル）−ｎ’−（４−フルオロフェニル）シクロプロパン−１，１−ジカルボキサミドを用いた尿路上皮癌及び他の尿生殖器悪性腫瘍の治療方法 |
| BR112019015011A2 (pt) * | 2017-01-20 | 2020-04-28 | Exelixis Inc | combinações de cabozantinibe e atezolizumabe para tratar câncer |
| GEAP202415420A (en) * | 2018-01-26 | 2024-12-25 | Exelixis Inc | Compounds for the treatment of kinase-dependent disorders |
| EP4631505A3 (en) * | 2018-12-13 | 2025-12-10 | Exelixis, Inc. | Crystalline forms and salt forms of a kinase inhibitor |
-
2021
- 2021-07-29 BR BR112023001792A patent/BR112023001792A2/pt unknown
- 2021-07-29 US US18/018,805 patent/US20230301979A1/en active Pending
- 2021-07-29 CA CA3186517A patent/CA3186517A1/en active Pending
- 2021-07-29 WO PCT/US2021/043699 patent/WO2022026706A1/en not_active Ceased
- 2021-07-29 CR CR20230052A patent/CR20230052A/es unknown
- 2021-07-29 KR KR1020237006875A patent/KR20230059792A/ko active Pending
- 2021-07-29 AU AU2021318134A patent/AU2021318134A1/en active Pending
- 2021-07-29 EP EP21758525.6A patent/EP4188376A1/en active Pending
- 2021-07-29 PH PH1/2023/550160A patent/PH12023550160A1/en unknown
- 2021-07-29 PE PE2023000162A patent/PE20231369A1/es unknown
- 2021-07-29 GE GEAP202616896A patent/GEAP202616896A/en unknown
- 2021-07-29 IL IL300151A patent/IL300151A/en unknown
- 2021-07-29 CN CN202180065378.8A patent/CN116437954A/zh active Pending
- 2021-07-29 MX MX2023001298A patent/MX2023001298A/es unknown
- 2021-07-29 JP JP2023506226A patent/JP7847576B2/ja active Active
- 2021-07-30 TW TW110128221A patent/TW202220654A/zh unknown
-
2023
- 2023-01-30 CL CL2023000289A patent/CL2023000289A1/es unknown
- 2023-02-14 CO CONC2023/0001561A patent/CO2023001561A2/es unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7122357B2 (ja) | がんの治療のための方法、組成物、及びキット | |
| CN111065411B (zh) | Pd-1抗体和vegfr抑制剂联合治疗小细胞肺癌的用途 | |
| JP6805336B2 (ja) | 薬学的組み合わせ | |
| JP2024095791A (ja) | 癌の処置のためのアパチニブを用いる併用療法 | |
| US12403154B2 (en) | Administration of sting agonist and checkpoint inhibitors | |
| US20200281923A1 (en) | Use of parp inhibitor in treating chemotherapy-resistant ovarian cancer or breast cancer | |
| JP2019525948A5 (enExample) | ||
| CN118401259A (zh) | 抗trop-2抗体偶联药物和其他治疗剂的组合用途 | |
| WO2021244551A1 (zh) | c-Met激酶抑制剂和抗PD-L1抗体的联用药物组合物 | |
| JP2024540417A5 (enExample) | ||
| TW202233206A (zh) | Ｓｔｉｎｇ促效劑、檢查點抑制劑及輻射之投與 | |
| CN113473989B (zh) | Sumo活化酶抑制剂和检查点抑制剂的施用 | |
| TW202541808A (zh) | 抗癌組合治療 | |
| WO2021180027A1 (zh) | 抗pd-1抗体和多受体酪氨酸激酶抑制剂的药物组合及其使用方法 | |
| CN116490244A (zh) | Sting激动剂、检查点抑制剂和辐射的施用 | |
| AU2024262533A1 (en) | Drug for treating locally advanced unresectable or metastatic colorectal cancer and use thereof | |
| CN118159538A (zh) | 含met受体酪氨酸激酶抑制剂的药物组合及应用 | |
| WO2026103822A1 (zh) | Ras抑制剂和pd-1或pd-l1抑制剂的组合及其用途 | |
| WO2025228596A1 (en) | Combination of pm14 and a topoisomerase i inhibitor in the treatment of cancer | |
| WO2026103823A1 (zh) | Ras抑制剂和egfr抑制剂的组合及其用途 | |
| WO2025232801A1 (zh) | 抗FRα抗体药物偶联物和PD-1拮抗剂在治疗肿瘤中的应用 | |
| TW202304450A (zh) | 以雄性素受體拮抗劑進行的轉移性去勢抗性前列腺癌患者之治療 | |
| CN116265030A (zh) | 包含酪氨酸激酶抑制剂德立替尼的药物组合 | |
| WO2026077321A1 (zh) | 抗her2抗体药物偶联物和免疫检查点抑制剂的药物组合 | |
| CN115779095A (zh) | 治疗结直肠癌的喹啉衍生物与pd-1单抗的药物组合 |